Allogene Therapeutics, Inc.
ALLO
$2.21
-$0.02-0.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -190.89M | -212.02M | -236.91M | -252.32M | -257.59M |
| Total Depreciation and Amortization | 12.36M | 12.54M | 12.65M | 13.18M | 13.64M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.16M | 46.54M | 62.78M | 69.25M | 68.45M |
| Change in Net Operating Assets | -10.88M | -5.41M | -11.29M | -27.44M | -24.80M |
| Cash from Operations | -149.25M | -158.35M | -172.77M | -197.33M | -200.30M |
| Capital Expenditure | -386.00K | -643.00K | -829.00K | -785.00K | -694.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.95M | 117.52M | 29.78M | 60.52M | 76.38M |
| Cash from Investing | 95.56M | 116.88M | 28.95M | 59.73M | 75.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23.25M | 21.13M | 18.58M | 123.39M | 114.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.91M | 6.91M | 6.91M | 5.63M | 2.28M |
| Cash from Financing | 30.16M | 28.04M | 25.48M | 129.02M | 116.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.53M | -13.42M | -118.34M | -8.58M | -7.94M |